Zimura® Shows Significant Suppression of Geographic Atrophy

IVERIC bio, Inc. has announced positive Phase 3 results from its GATHER1 clinical trial with Zimura® (avacincaptad pegol). As published in the September issue of Ophthalmology®, Zimura® met its pre-specified primary efficacy endpoint at 12 months and reached statistical significance in GATHER1, an international, multicenter, randomized, double masked, sham controlled clinical trial.  Zimura® inhibits complement [Read More]

AAO Cautions About Red Light Therapy

An article published here in August 2020 announced that positive results were obtained from a study of photobiomodulation (PBM)–also known as “red light therapy”– as a treatment for eye diseases such as AMD, retinopathy of prematurity, and diabetic macular edema. The American Academy of Ophthalmology has simultaneously posted cautionary remarks about recent PBM research. In [Read More]

Light Therapy Showing Success As Retinal Treatment

According to an article in the August 6, 2020 edition of Ophthalmology Times, a procedure called photobiomodulation (PBM) has had recent success in treating eye diseases such as AMD, retinopathy of prematurity, and diabetic macular edema. PBM, or low-level light therapy, is the application of monochromatic light to a part of the body with the [Read More]